Positive recommendation in NICE draft guidance follows receipt of additional information and extensive liaison with the company.

Treatment accepted for restricted use within NHS Scotland.

Randomised phase III study showed secukinumab significantly improved symptoms compared with placebo.

Treatments for multiple myeloma, lung cancer and lymphoma accepted for use within NHS Scotland.

Genetic testing should not delay urgently needed aminoglycoside treatment but may be considered, especially before the start of recurrent or long-term treatment.

Prescribers should consider this risk in the context of an individual patient’s bleeding and thrombotic risk assessment during the peripartum period and the benefits of antidepressants for the patient’s mental health during this time.

Liver monitoring requirements and discontinuation criteria for fingolimod have been updated following reports of serious liver injury.

The monitoring requirements and discontinuation criteria for dimethyl fumarate (Tecfidera) have been strengthened following a small number of reports of progressive multifocal leukoencephalopathy (PML) in patients with mild lymphopenia.